NasdaqCM - Nasdaq Real Time Price USD

Heron Therapeutics, Inc. (HRTX)

2.1100
-0.0600
(-2.76%)
At close: May 9 at 4:00:01 PM EDT
2.1200
+0.01
+(0.47%)
After hours: May 9 at 5:52:45 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
148,518
144,285
127,044
107,672
86,346
Cost of Revenue
38,661
38,648
65,105
54,874
46,021
Gross Profit
109,857
105,637
61,939
52,798
40,325
Operating Expense
113,433
117,165
172,554
227,456
258,153
Operating Income
-3,576
-11,528
-110,615
-174,658
-217,828
Net Non Operating Interest Income Expense
--
-2,482
-504
-836
-1,977
Other Income Expense
-1,727
430
560
-6,530
-878
Pretax Income
-7,785
-13,580
-110,559
-182,024
-220,683
Net Income Common Stockholders
-7,785
-13,580
-110,559
-182,024
-220,683
Diluted NI Available to Com Stockholders
-7,785
-13,580
-110,559
-182,024
-220,683
Basic EPS
-0.05
--
-0.80
-1.67
-2.24
Diluted EPS
-0.05
--
-0.80
-1.67
-2.24
Basic Average Shares
153,021.7500
--
138,135
108,996.4070
98,471
Diluted Average Shares
153,021.7500
--
138,135
108,996.4070
98,471
Total Operating Income as Reported
-3,576
-11,528
-110,615
-174,658
-217,828
Total Expenses
152,094
155,813
237,659
282,330
304,174
Net Income from Continuing & Discontinued Operation
-7,785
-13,580
-110,559
-182,024
-220,683
Normalized Income
-7,785
-13,580
-110,559
-182,024
-220,683
Interest Income
--
3,550
3,364
1,638
433
Interest Expense
--
6,032
3,868
2,474
2,410
Net Interest Income
--
-2,482
-504
-836
-1,977
EBIT
404
-7,548
-106,691
-179,550
-218,273
EBITDA
2,758
-5,056
-103,792
-176,661
-215,252
Reconciled Cost of Revenue
38,661
38,648
65,105
54,874
46,021
Reconciled Depreciation
2,354
2,492
2,899
2,889
3,021
Net Income from Continuing Operation Net Minority Interest
-7,785
-13,580
-110,559
-182,024
-220,683
Normalized EBITDA
2,758
-5,056
-103,792
-176,661
-215,252
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 8/26/1987

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CTMX CytomX Therapeutics, Inc.
0.9284
-14.83%
 
RIGL Rigel Pharmaceuticals, Inc.
18.77
-0.69%
 
GLMD Galmed Pharmaceuticals Ltd.
1.2400
-0.80%
 
PSTV Plus Therapeutics, Inc.
0.6600
+6.45%
 
ARDX Ardelyx, Inc.
3.6200
-0.55%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5272
-7.70%
 
ACAD ACADIA Pharmaceuticals Inc.
17.44
+3.01%
 
CRVS Corvus Pharmaceuticals, Inc.
4.4300
+32.24%
 
AXSM Axsome Therapeutics, Inc.
107.76
-1.01%
 
NKTR Nektar Therapeutics
0.5887
-4.88%